BABlanca Aguilar-Barrera

Blanca Aguilar-Barrera

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Blanca Aguilar-Barrera has a total of 36 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Ocular Complications Related to Iris-Fixated Phakic Intraocular Lens Implantation: A Systematic Review and Meta-Analysis

    by Germán Mejía-Salgado, Blanca Aguilar-Barrera, Paula Alejandra Navarro, Diana Carolina Cortés-Jaimes, Ana María Núñez-Pardo, Juan Daniel Ribero, Santiago Espinosa-Lugo, Laura Daniela Rodríguez-Camelo, Joaquín Alonso Pérez-Vivas, Lizeth Catherine Rodríguez-Corredor, et al.

    Topic: This systematic review and meta-analysis evaluated the cumulative prevalence of ocular complications following implantation of Artisan ® /Verisyse ® iris-fixated phakic intraocular lenses in adult patients undergoing refractive surgery. Outcomes included postoperative ocular complications and longitudinal loss of endothelial cell density (ECD). Clinical relevance: Phakic intraocular lenses are widely used to correct moderate-to-high refractive errors. Available evidence on complication rates is heterogeneous and often limited to narrative reports, hindering accurate risk counseling and long-term clinical decision-making. Methods: This study was conducted according to PRISMA guidelines and was registered in PROSPERO (CRD420251150677). Eligible studies included ≥10 eyes implanted with Artisan ® /Verisyse ® lenses reporting postoperative complications. Risk of bias was assessed using design-specific tools. Proportion meta-analyses were performed with subgroup analyses comparing real-world evidence studies versus clinical trials. ECD loss was analyzed from three months to 10 years post-implantation. Certainty of evidence was evaluated using GRADE. Results: Fifty-five studies were included. Iris atrophy was the most common complication (20.3%, 95% CI: 5.7-52.1). Other complications included pupil ovalization (7.6%, 95% CI: 4.8-12.5), progressive reduction in visual acuity (7.6%, 95% CI: 5.8-9.5), position-related complications (including rotation, dislocation, subluxation, and luxation) (6.7%, 95% CI: 1.9-33.4), uveitis (6.2%, 95% CI: 4.3-9.1), and halos (5.3%, 95% CI: 3.2-7.9). Ocular hypertension (4.7%, 95% CI: 2.4-7.9), cataract (2.8%, 95% CI: 1.6-3.5), corneal decompensation (2.6%, 95% CI: 1.8-6.5), and retinal detachment (1.1%, 95% CI: 0.7-1.3) occurred less frequently. Subgroup analyses showed higher rates of corneal decompensation in real-world studies (4.2% vs. 1.3%; p = 0.04) and traumatic position-related complications (5.0% vs. 0.8%; p = 0.02), whereas ocular hypertension was more frequent in clinical trials (14.1% vs. 2.3%; p < 0.01). ECD loss increased from 5.3% at 3 months to 15.8% at 10 years. Certainty of evidence ranged from very low to moderate, with substantial heterogeneity across outcomes. Conclusion: Despite overall acceptable safety, Artisan ® /Verisyse ® implantation is associated with measurable ocular complications and progressive ECD loss.

  • The Stalagmite Sign: A Novel Optical Coherence Tomography-Infrared Biomarker for Peripheral Infectious Retinitis

    by Andres F. Lasave, Ariel Schlaen, Daniel N. Colombero, Cristhian A. Urzua, Anupam K. Garg, Lorena B. Saieg, Agustina B. Nieddu, Maria Agustina Gómez-Chapo, Blanca S. Aguilar-Barrera, Tomas Castro-Feijoo, et al.

  • Open Access

    Efficacy, effectiveness, and safety of rho-kinase inhibitors in uveitic glaucoma and ocular hypertension secondary to uveitis: a systematic review and meta-analysis

    by Blanca Aguilar-Barrera, Germán Mejía-Salgado, Juanita Cardona-López, Alejandra Reyes-Troncoso, Santiago David Acosta-Alzamora, David Santiago Escobar-Sánchez, Fábian Andrés Guauque, Ana María Camacho-Romero, Valentina Suarez-Carreño, Stefania García-García, et al.

    Purpose: To evaluate the efficacy, effectiveness, and safety of Rho-kinase (ROCK) inhibitors in the management of uveitic glaucoma (UG) and ocular hypertension secondary to uveitis (OHT-SU) through a systematic review and meta-analysis. Methods: We systematically searched PubMed, EMBASE, Virtual Health Library, and medRxiv databases until October 29, 2024, for studies evaluating UG or OHT-SU patients treated with ROCK inhibitors. Eligible designs included case series with over 10 patients, cross-sectional studies, cohort studies, and randomized controlled trials. Risk of bias was assessed using the CLARITY tools and validated metrics such as those developed by Hoy et al., Hassan Murad et al., and the RoB-2 tool. A pressure (IOP) reduction meta-analysis at different follow-up points was conducted using R software. The study was registered in PROSPERO with the CRD42024618812 number. Results: Eleven studies (383 participants, 256 eyes) were analyzed. Some studies reported outcomes per eye, whereas others reported outcomes only per patient; thus, the number of eyes reflects only explicitly reported data. Based on the risk of bias assessment, two studies had a low risk of bias, four raised some concerns, and five were at high risk of bias. Pooled mean age was 64.2 ± 15.2 years (from 10 studies reporting age); sex distribution (50.5% male, 49.5% female, from 7 studies reporting gender). ROCK inhibitors achieved a statistically significant reduction in IOP at 3 months (mean difference: -9.32 mmHg, 95% CI: -17.02 to -1.62). These effects were sustained at 12 months (-7.92 mmHg, 95% CI: -10.28 to -5.56). Combination therapy enhanced pressure control. The most common adverse event was conjunctival hyperemia, with a pooled prevalence of 6% (95% CI: 3%-15%), followed by ocular pain and blurred vision. Importantly, no major safety differences were found between ripasudil and netarsudil. Additionally, ROCK inhibitors also improved surgical outcomes in UG patients. Conclusion: ROCK inhibitors demonstrate significant and sustained IOP-lowering effects in UG and OHT-SU with a favorable safety profile. Their additive effect with conventional treatments and potential benefits in surgical outcomes highlight their role as promising therapeutic agents. Further clinical trials are needed to compare different ROCK inhibitors and assess their long-term safety and effectiveness in different populations.